Grant opportunity · PAR-25-025
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
Who can apply (as listed)
- Special district governments
- Independent school districts
- State governments
- Private institutions of higher education
- Nonprofits with 501(c)(3) status (other than institutions of higher education)
- City or township governments
- Native American tribal governments (federally recognized)
- Public housing authorities / Indian housing authorities
- Nonprofits without 501(c)(3) status (other than institutions of higher education)
- Native American tribal organizations (other than federally recognized governments)
- Public and state-controlled institutions of higher education
- Small businesses
- County governments
- Others (see the opportunity text)
- For-profit organizations (other than small businesses)
The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO which utilizes an R61/R33 phased approach.
Excerpt as published. The full synopsis, required forms, and any amendments are on the official listing.
GrantSet indexes public records and is not the official application channel. Responses and applications go through Grants.gov only — the official notice there controls if anything shown here differs.